Previous close | 423.50 |
Open | 409.75 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 423.50 - 423.50 |
52-week range | 340.10 - 473.65 |
Volume | |
Avg. volume | 87 |
Market cap | 275.806B |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | 22.57 |
EPS (TTM) | 18.76 |
Earnings date | N/A |
Forward dividend & yield | 9.97 (2.35%) |
Ex-dividend date | 17 Mar 2022 |
1y target est | N/A |
Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.
By Scott Kanowsky
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age The FDA also approved Xofluza to prevent influenza in children aged five years and older following contact with an infected person Basel, 12 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (balo